S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
5 Stocks to Buy Immediately (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Stocks are for suckers – try this instead (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Stocks are for suckers – try this instead (Ad)
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
5 Stocks to Buy Immediately (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Stocks are for suckers – try this instead (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Stocks are for suckers – try this instead (Ad)
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
5 Stocks to Buy Immediately (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Stocks are for suckers – try this instead (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Stocks are for suckers – try this instead (Ad)
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
5 Stocks to Buy Immediately (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Stocks are for suckers – try this instead (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Stocks are for suckers – try this instead (Ad)
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
NASDAQ:NKTR

Nektar Therapeutics - NKTR Stock Forecast, Price & News

$0.70
+0.07 (+11.06%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.62
$0.71
50-Day Range
$0.64
$3.15
52-Week Range
$0.60
$6.26
Volume
16.15 million shs
Average Volume
3.85 million shs
Market Capitalization
$133.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.08

Nektar Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
1.50 Rating Score
Upside/​Downside
338.7% Upside
$3.08 Price Target
Short Interest
Healthy
3.74% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.77
Upright™ Environmental Score
News Sentiment
0.66mentions of Nektar Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$121,158 Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.49 out of 5 stars

Medical Sector

152nd out of 1,004 stocks

Pharmaceutical Preparations Industry

62nd out of 489 stocks


NKTR stock logo

About Nektar Therapeutics (NASDAQ:NKTR) Stock

Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.

Receive NKTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NKTR Stock News Headlines

Stocks are for suckers – try this instead
This has nothing to do with dividends, day trading... taking out a loan... or anything like that. What you need is about 3 seconds to execute this simple financial maneuver...
Nektar (NKTR) Upgraded to Buy: Here's Why
Brokerages Set Nektar Therapeutics (NASDAQ:NKTR) PT at $3.08
Analyst Ratings for Nektar Therapeutics
Sell every Stock except ONE
Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...
Why Is Nektar Therapeutics (NKTR) Stock Down 39% Today?
Nektar Therapeutics: Recovery Seems To Be A Mirage
See More Headlines
Receive NKTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NKTR Company Calendar

Last Earnings
2/28/2023
Today
4/01/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:NKTR
CUSIP
64026810
Employees
740
Year Founded
1990

Price Target and Rating

Average Stock Price Forecast
$3.08
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+338.7%
Consensus Rating
Hold
Rating Score (0-4)
1.50
Research Coverage
6 Analysts

Profitability

Net Income
$-368,200,000.00
Net Margins
-399.98%
Pretax Margin
-396.48%

Debt

Sales & Book Value

Annual Sales
$92.06 million
Book Value
$1.95 per share

Miscellaneous

Free Float
182,839,000
Market Cap
$133.01 million
Optionable
Optionable
Beta
1.10

Social Links


Key Executives

  • Howard W. RobinHoward W. Robin
    President, Chief Executive Officer & Director
  • Jillian B. ThomsenJillian B. Thomsen
    Chief Financial Officer & Senior Vice President
  • Jonathan ZalevskyJonathan Zalevsky
    Chief Research & Development Officer
  • Brian L. Kotzin
    Chief Medical Officer & Senior Vice President
  • Mary Tagliaferri
    Chief Development Officer & Senior Vice President













NKTR Stock - Frequently Asked Questions

Should I buy or sell Nektar Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last twelve months. There are currently 3 sell ratings and 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NKTR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NKTR, but not buy additional shares or sell existing shares.
View NKTR analyst ratings
or view top-rated stocks.

What is Nektar Therapeutics' stock price forecast for 2023?

6 Wall Street analysts have issued 1 year price targets for Nektar Therapeutics' stock. Their NKTR share price forecasts range from $1.50 to $6.00. On average, they expect the company's stock price to reach $3.08 in the next year. This suggests a possible upside of 338.7% from the stock's current price.
View analysts price targets for NKTR
or view top-rated stocks among Wall Street analysts.

How have NKTR shares performed in 2023?

Nektar Therapeutics' stock was trading at $2.26 at the start of the year. Since then, NKTR shares have decreased by 68.9% and is now trading at $0.7029.
View the best growth stocks for 2023 here
.

Are investors shorting Nektar Therapeutics?

Nektar Therapeutics saw a decline in short interest during the month of March. As of March 15th, there was short interest totaling 7,080,000 shares, a decline of 19.1% from the February 28th total of 8,750,000 shares. Based on an average daily trading volume, of 2,430,000 shares, the short-interest ratio is currently 2.9 days.
View Nektar Therapeutics' Short Interest
.

When is Nektar Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our NKTR earnings forecast
.

How were Nektar Therapeutics' earnings last quarter?

Nektar Therapeutics (NASDAQ:NKTR) released its quarterly earnings results on Tuesday, February, 28th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.11. The biopharmaceutical company had revenue of $22.02 million for the quarter, compared to the consensus estimate of $22.21 million. Nektar Therapeutics had a negative net margin of 399.98% and a negative trailing twelve-month return on equity of 76.92%. Nektar Therapeutics's revenue for the quarter was down 11.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.79) earnings per share.

What ETFs hold Nektar Therapeutics' stock?
What is Howard W. Robin's approval rating as Nektar Therapeutics' CEO?

46 employees have rated Nektar Therapeutics Chief Executive Officer Howard W. Robin on Glassdoor.com. Howard W. Robin has an approval rating of 81% among the company's employees.

What other stocks do shareholders of Nektar Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), Netflix (NFLX) and Incyte (INCY).

What is Nektar Therapeutics' stock symbol?

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

How do I buy shares of Nektar Therapeutics?

Shares of NKTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nektar Therapeutics' stock price today?

One share of NKTR stock can currently be purchased for approximately $0.70.

How much money does Nektar Therapeutics make?

Nektar Therapeutics (NASDAQ:NKTR) has a market capitalization of $133.01 million and generates $92.06 million in revenue each year. The biopharmaceutical company earns $-368,200,000.00 in net income (profit) each year or ($1.97) on an earnings per share basis.

How many employees does Nektar Therapeutics have?

The company employs 740 workers across the globe.

How can I contact Nektar Therapeutics?

Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The official website for the company is www.nektar.com. The biopharmaceutical company can be reached via phone at (415) 482-5300, via email at investors@nektar.com, or via fax at 415-339-5300.

This page (NASDAQ:NKTR) was last updated on 4/1/2023 by MarketBeat.com Staff